← Back to Search

Other

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL Trial)

Phase 2
Waitlist Available
Research Sponsored by Bionomics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a medication called BNC210 to see if it can help reduce anxiety in people with Social Anxiety Disorder. Participants will take a single dose of BNC210 and then do a speaking challenge. The goal is to find out if BNC210 can make them feel less anxious.

Eligible Conditions
  • Social Anxiety Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 675 mg BNC210Experimental Treatment1 Intervention
Group II: 225 mg BNC210Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
225 mg BNC210
2022
Completed Phase 2
~160
675 mg BNC210
2022
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Bionomics LimitedLead Sponsor
7 Previous Clinical Trials
951 Total Patients Enrolled
~39 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top